A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Trial Profile

A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Pelareorep (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 11 Sep 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2018.
    • 11 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top